What's in ViiV Healthcare's pipeline?

ViiV Healthcare has 118 drugs in our index: 21 marketed, 0 filed, 33 in Phase 3, 19 in Phase 2, 45 in Phase 1.

Which companies overlap with ViiV Healthcare's portfolio?

Top competitors by shared drug class: National Institute of Allergy and Infectious Diseases (NIAID), French National Agency for Research on AIDS and Viral Hepatitis, Merck Sharp & Dohme LLC, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, Bristol-Myers Squibb.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/viiv-healthcare.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

ViiV Healthcare — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ViiV Healthcare pipeline: 21 marketed, 0 filed, 33 Phase 3, 19 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

21 marketed 0 filed 33 Phase 3 19 Phase 2 45 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
HIV therapy	HIV therapy	marketed	Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors)	Multiple targets depending on specific agent (HIV reverse transcriptase, HIV protease, HIV integrase, CCR5 co-receptor, gp120/gp41 envelope proteins)	Infectious Disease / Virology
Lenacapavir long-acting	Lenacapavir long-acting	marketed	HIV capsid inhibitor	HIV capsid protein	Infectious Disease
Dolutegravir (DTG)	Dolutegravir (DTG)	marketed	Integrase strand transfer inhibitor (INSTI)	HIV integrase	Infectious Disease
APRETUDE	APRETUDE	marketed
Fosamprenavir/ritonavir	Fosamprenavir/ritonavir	marketed	HIV protease inhibitor	HIV protease	Infectious Disease
Cabotegravir Injectable Suspension	Cabotegravir Injectable Suspension	marketed	Integrase strand transfer inhibitor (INSTI)	HIV integrase	Infectious Disease
CAR	CAR	marketed	Antiretroviral combination therapy (INSTI + NNRTI)	HIV integrase and HIV reverse transcriptase	Infectious Disease / Virology
Reyataz + Epzicom	Reyataz + Epzicom	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase	Infectious Disease / Virology
Reyataz + Norvir + Truvada	Reyataz + Norvir + Truvada	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase	Infectious Disease / Virology
Ortho Cyclen	Ortho Cyclen	marketed
CABENUVA	CABENUVA	marketed			Infectious Disease
JULUCA	JULUCA	marketed	Antiretroviral combination (integrase inhibitor + NNRTI)	HIV integrase and HIV reverse transcriptase	Infectious Disease / Virology

Therapeutic area mix

Infectious Disease / Virology · 29
Infectious Disease · 22
Infectious Diseases · 3
Other · 2
Infectious disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

National Institute of Allergy and Infectious Diseases (NIAID) · 7 shared drug classes
French National Agency for Research on AIDS and Viral Hepatitis · 6 shared drug classes
Merck Sharp & Dohme LLC · 5 shared drug classes
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 4 shared drug classes
Bristol-Myers Squibb · 4 shared drug classes
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 3 shared drug classes
GlaxoSmithKline · 3 shared drug classes
ANRS, Emerging Infectious Diseases · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for ViiV Healthcare:

Cite this brief

Drug Landscape (2026). ViiV Healthcare — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/viiv-healthcare. Accessed 2026-05-18.